Can you continue checkpoint inhibitor therapy in the setting of severe cutaneous irAE while concurrently treating the cutaneous reaction?

Cutaneous reactions from immune checkpoint inhibitors (ICPi) generally fit into 3 categories: rash/inflammatory dermatitis, bullous dermatoses, and severe cutaneous adverse reaction (SCAR). For grade 1-2 rash/inflammatory dermatitis, if symptoms can be managed with topical therapy or non-steroidal o...

Yes, there is more data to be had. We do not know the right answers for this. There are some fundamental guidelines,

Cancer side effects are defined by grades 1-4. Grades 3-4 often immunotherapy is held and possibly rechallenge - more data is needed. At the moment use your team of experts and each pa...